Journal of the Neurological Sciences
Volume 222, Issue 1 , Pages 49-53 , 15 July 2004

Maintained regulation of polyamines in spinal cord from patients with amyotrophic lateral sclerosis

  • Titti Ekegren

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +46-18-611-26-69; fax: +46-18-611-50-27.
    • Department of Neuroscience, Neurology, University Hospital, Uppsala SE-751 85, Sweden
    • ,
  • Cecilia Gomes-Trolin

      Affiliations

    • NeoPharma AB, Fyrisborgsgatan 3, Uppsala SE-751 03, Sweden
    • ,
  • Ingela Nygren

      Affiliations

    • Department of Neuroscience, Neurology, University Hospital, Uppsala SE-751 85, Sweden
    • ,
  • Håkan Askmark

      Affiliations

    • Department of Neuroscience, Neurology, University Hospital, Uppsala SE-751 85, Sweden

Received 28 January 2004 ,Accepted 5 April 2004.

References 

  1. Brown RHj, Meininger V, Swash M. Amyotrophic lateral sclerosis. London: Martin Dunitz; 2000;
  2. Plaitakis A, Shashidharan P. In:  Bloom FE,  Kupfer DJ editor. Psychopharmacology: the fourth generation of progress. New York: Raven Press; 1995;p. 1531
  3. Shaw PJ, Ince PG. Glutamate, excitotoxicity and amyotrophic lateral sclerosis. J. Neurol. 1997;244(Suppl. 2):S3
  4. Louvel E, Hugon J, Doble A. Therapeutic advances in amyotrophic lateral sclerosis. Trends Pharmacol. Sci. 1997;18:196
  5. Xu L, Enyeart JA, Enyeart JJ. Neuroprotective agent riluzole dramatically slows inactivation of Kv1.4 potassium channels by a voltage-dependent oxidative mechanism. J. Pharmacol. Exp. Ther. 2001;299:227
  6. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N. Engl. J. Med. 1994;330:585
  7. Carter CJ. Neuropharmacology of polyamines. London: Academic Press; 1994;
  8. Bernstein HG, Muller M. The cellular localization of the l-ornithine decarboxylase/polyamine system in normal and diseased central nervous systems. Prog. Neurobiol. 1999;57:485
  9. Tabor CW, Tabor H. Polyamines. Annu. Rev. Biochem. 1984;53:749
  10. Thomas T, Thomas TJ. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell. Mol. Life Sci. 2001;58:244
  11. Heby O. Role of polyamines in the control of cell proliferation and differentiation. Differentiation. 1981;19:1
  12. Williams K. Modulation and block of ion channels: a new biology of polyamines. Cell Signal. 1997;9:1
  13. Scott RH, Sutton KG, Dolphin AC. Interactions of polyamines with neuronal ion channels. Trends. Neurosci. 1993;16:153
  14. Jeevanandam M, Ali MR, Young DH, Schiller WR. Polyamine levels as biomarkers of injury response in polytrauma victims. Metabolism. 1989;38:625
  15. Mautes AE, Paschen W, Rohn G, Nacimiento AC. Changes in ornithine decarboxylase activity and putrescine concentrations after spinal cord compression injury in the rat. Neurosci. Lett. 1999;264:153
  16. Paschen W. Polyamine metabolism in reversible cerebral ischemia. Cereb. Brain Metab. Rev. 1992;4:59
  17. Henley CM, Muszynski C, Cherian L, Robertson CS. Activation of ornithine decarboxylase and accumulation of putrescine after traumatic brain injury. J. Neurotrauma. 1996;13:487
  18. Seidl R, Beninati S, Cairns N, Singewald N, Risser D, Bavan H, et al.  Polyamines in frontal cortex of patients with Down syndrome and Alzheimer disease. Neurosci. Lett. 1996;206:193
  19. Morrison LD, Kish SJ. Brain polyamine levels are altered in Alzheimer's disease. Neurosci. Lett. 1995;197:5
  20. Russell DH, Stern LZ. Altered polyamine excretion in Duchenne muscular dystrophy. Neurology. 1981;31:80
  21. Kaminska AM, Stern LZ, Russell DH. Altered muscle polyamine levels in human neuromuscular diseases. Ann. Neurol. 1981;9:605
  22. Szathmary I, Selmeci L, Szobor A, Molnar J. Altered polyamine levels in skeletal muscle of patients with myasthenia gravis. Clin. Neuropathol. 1994;13:181
  23. Nitta T, Igarashi K, Yamamoto N. Polyamine depletion induces apoptosis through mitochondria-mediated pathway. Exp. Cell Res. 2002;276:120
  24. Seiler N. Oxidation of polyamines and brain injury. Neurochem. Res. 2000;25:471
  25. Schipper RG, Penning LC, Verhofstad AAJ. Involvement of polyamines in apoptosis. Facts and controversies: effectors or protectors?. Cancer Biol. 2000;0:55
  26. Brooks WH. Polyamine involvement in the cell cycle, apoptosis, and autoimmunity. Med. Hypotheses. 1995;44:331
  27. Cestaro B. Effects of arginine, S-adenosylmethionine and polyamines on nerve regeneration. Acta Neurol. Scand. 1994;154:32
  28. Drolet G, Dumbroff EB, Legge RL, Thompson JE. Radical scavenging properties of polyamines. Phytochemistry. 1986;25:367
  29. Gilad GM, Gilad VH. Novel polyamine derivatives as neuroprotective agents. J. Pharmacol. Exp. Ther. 1999;291:39
  30. Munir M, Subramaniam S, McGonigle P. Polyamines modulate the neurotoxic effects of NMDA in vivo. Brain Res. 1993;616:163
  31. Gomes-Trolin C, Nygren I, Aquilonius SM, Askmark H. Increased red blood cell polyamines in ALS and Parkinson's disease. Exp. Neurol. 2002;177:515
  32. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors. J. Neurol. Sci. 1994;124:96; [Supplement]
  33. Norris FH, Calanchini PR, Fallat RJ, Panchari S, Jewett B. The administration of guanidine in amyotrophic lateral sclerosis. Neurology. 1974;24:721
  34. Markwell MA, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 1978;87:206
  35. Einarsson S, Josefsson B, Lagerkvist S. Determination of aminoacids with 9-fluorenylmethyl chloroformate and reversed-phase high-performance liquid chromatography. J. Chromatogr. 1983;282:608
  36. Huhn G, Mattusch J, Schulz H. Determination of polyamines in biological-materials by HPLC with 9-fluorenylmethyl chloroformate precolumn derivatization. Fresenius' J. Anal. Chem. 1995;351:563
  37. Maier-Rosenkrantz J, Maisch A, Kupka A, Földi P. Superior precolumn derivatization of biological amines with fluorenyl derivatives using the ADAM-EVE approach. LC-GC Int. 1994;7:509
  38. Vivó M, de Vera N, Cortes R, Mengod G, Camon L, Martinez E. Polyamines in the basal ganglia of human brain. Influence of aging and degenerative movement disorders. Neurosci. Lett. 2001;304:107
  39. Morrison LD, Becker L, Ang LC, Kish SJ. Polyamines in human brain: regional distribution and influence of aging. J. Neurochem. 1995;65:636
  40. Chaudhuri D, Choudhury I, Mukherjea M. Ontogeny of polyamines in relation to nucleic acids in brain and spinal cord of the developing human fetus. Brain Res. 1983;312:143
  41. Shaw GG, Pateman AJ. The regional distribution of the polyamines spermidine and spermine in brain. J. Neurochem. 1973;20:1225
  42. Virgili M, Necchi D, Scherini E, Contestabile A. Increase of the ornithine decarboxylase/polyamine system and transglutaminase upregulation in the spinal cord of aged rats. Neurosci. Lett. 2001;309:62
  43. Gonzalez S, Coirini H, Gonzalez Deniselle MC, Calandra R, De Nicola AF. Time-dependent effects of dexamethasone on glutamate binding, ornithine decarboxylase activity and polyamine levels in the transected spinal cord. J. Steroid Biochem. Mol. Biol. 1995;55:85

PII: S0022-510X(04)00106-6

doi: 10.1016/j.jns.2004.04.011

Journal of the Neurological Sciences
Volume 222, Issue 1 , Pages 49-53 , 15 July 2004

Article Tools

* Image Usage & Resolution